Abstract:Inflammatory conditions elicited by extrinsic environmental factors promote malignant transformation, tumor growth and metastasis. Although the role of T cells in cancer promotion has been examined, little is known about the underlying molecular mechanisms of interleukin-17 A (IL-17A), a proinflammatory cytokine produced by activated CD4(+) memory T cells, in carcinogenesis. Here, we report that IL-17A induces neoplastic transformation of JB6 Cl41 cells through activation of tumor progression locus 2 (TPL2). IL-17A dose- and time-dependently increases TPL2 phosphorylation in JB6 Cl41 cells through IL-17A receptor. IL-17A activates mitogen-activated protein kinase/extracellular signal-regulated kinase kinases, c-jun N-terminal kinases and STAT3 signaling pathways, which are inhibited by a TPL2 kinase inhibitor (TKI). Furthermore, IL-17A activates c-fos and c-jun promoter activity, resulting in increased activator protein-1 (AP-1) activity. When small interfering RNA of IL-17A receptor (IL-17R), IL-17A and TPL2 were introduced into JB6 Cl41 cells, respectively, IL-17A-induced AP-1 activity was significantly decreased compared with control cells. Similarly, TPL2 inhibition suppressed AP-1 activity induced by IL-17A. The knockdown of IL-17R and TKI treatment in JB6 Cl41 cells resulted in decreased IL-17A-induced cell transformation. The in vivo chorioallantoic membrane assay also showed that IL-17A increased tumor formation of JB6 Cl41 cells, whereas TKI inhibited the tumorigenesis promoted by IL-17A. Consistent with these observations, knockdown of IL-17A and/or inhibition of TPL2 attenuated tumorigenicity of human breast cancer MCF7 cells. Together, our findings point to a critical role for the IL-17A-induced TPL2 signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may, therefore, effectively inhibit carcinogenesis.

Interleukin-38 promotes skin tumorigenesis via regulation of epidermal cell hyperplasia and pro-tumorigenic microenvironment in an IL-1Rrp2-dependent manner.

Interleukin-38 Promotes Skin Tumorigenesis in an IL-1Rrp2-dependent Manner.

IL‐38 orchestrates proliferation and differentiation in human keratinocytes

Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103+DC cells

Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling

Interleukin-38 promotes tumor growth through regulation of CD8+ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment

IL-38 promotes the development of prostate cancer

Interleukin-38 overexpression in keratinocytes limits desquamation but does not affect the global severity of imiquimod-induced skin inflammation in mice

The Role of Interleukin-17A in Colorectal Tumorigenesis

Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction

Potential pro‐tumour cytokine in oral squamous cellular carcinoma: IL37

Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process

IL-38 Aggravates Atopic Dermatitis via Facilitating Migration of Langerhans cells

A Novel IL-17 Signaling Pathway Controlling Keratinocyte Proliferation and Tumorigenesis Via the TRAF4–ERK5 Axis

The Role of IL-37 and IL-38 in Colorectal Cancer

The role of IL-38 in intestinal diseases - its potential as a therapeutic target

Interleukin-37 expression and its potential role in oral leukoplakia and oral squamous cell carcinoma

Elucidating The Role Of Interleukin-17f In Cutaneous T-Cell Lymphoma

IL-1 Signaling Regulates Skin Inflammation Through Directly Activating and Indirectly Chemoattracting Dermal Γδ T17 Cells (CAM1P.147)

Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity

Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy